IMBiologics Corp. (KOSDAQ:493280)
50,900
-2,800 (-5.21%)
At close: Apr 29, 2026
IMBiologics Market Cap
IMBiologics has a market cap or net worth of 718.12 billion as of April 30, 2026.
Market Cap
718.12B
Enterprise Value
n/a
Revenue
n/a
Ranking
n/a
PE Ratio
n/a
Stock Price
50,900.00
Market Cap Chart
Since March 20, 2026, IMBiologics's market cap has decreased from 1.54T to 718.12B, a decrease of -53.27%. That is a compound annual growth rate of -99.89%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 30, 2026 | 718.12B | -4.52% |
| Apr 29, 2026 | 752.10B | -5.21% |
| Apr 28, 2026 | 793.48B | -3.59% |
| Apr 27, 2026 | 823.03B | 3.92% |
| Apr 24, 2026 | 792.00B | 3.08% |
| Apr 23, 2026 | 768.36B | 1.17% |
| Apr 22, 2026 | 759.49B | -6.72% |
| Apr 21, 2026 | 814.16B | -10.11% |
| Apr 20, 2026 | 905.78B | 5.33% |
| Apr 17, 2026 | 859.97B | -4.90% |
| Apr 16, 2026 | 904.30B | -0.49% |
| Apr 15, 2026 | 908.73B | 0.99% |
| Apr 14, 2026 | 899.87B | 7.98% |
| Apr 13, 2026 | 833.37B | 14.87% |
| Apr 10, 2026 | 725.51B | 3.48% |
| Apr 9, 2026 | 701.13B | -6.04% |
| Apr 8, 2026 | 746.19B | 15.83% |
| Apr 7, 2026 | 644.24B | -5.93% |
| Apr 6, 2026 | 684.87B | -1.07% |
| Apr 3, 2026 | 692.26B | -4.49% |
| Apr 2, 2026 | 724.77B | -14.99% |
| Apr 1, 2026 | 852.58B | 4.34% |
| Mar 31, 2026 | 817.12B | -15.83% |
| Mar 30, 2026 | 970.79B | -12.28% |
| Mar 27, 2026 | 1.11T | -3.10% |
| Mar 26, 2026 | 1.14T | 7.06% |
| Mar 25, 2026 | 1.07T | -2.43% |
| Mar 24, 2026 | 1.09T | -2.76% |
| Mar 23, 2026 | 1.12T | -26.83% |
| Mar 20, 2026 | 1.54T | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Qurient | 1.66T |
| JS Link | 1.51T |
| AprilBio | 1.48T |
| ROKIT Healthcare | 1.39T |
| Curocell | 938.44B |
| Inventage Lab | 861.70B |
| IntoCell | 603.13B |
| Kanaph Therapeutics | 517.17B |